197 related articles for article (PubMed ID: 37522565)
1. Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of Cancer.
Rizwi FA; Abubakar M; Puppala ER; Goyal A; Bhadrawamy CV; Naidu VGM; Roshan S; Tazneem B; Almalki WH; Subramaniyan V; Rawat S; Gupta G
J Environ Pathol Toxicol Oncol; 2023; 42(4):15-29. PubMed ID: 37522565
[TBL] [Abstract][Full Text] [Related]
2. JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.
Springuel L; Renauld JC; Knoops L
Haematologica; 2015 Oct; 100(10):1240-53. PubMed ID: 26432382
[TBL] [Abstract][Full Text] [Related]
3. Mining for JAK-STAT mutations in cancer.
Constantinescu SN; Girardot M; Pecquet C
Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658
[TBL] [Abstract][Full Text] [Related]
4. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
5. JAK/STAT in leukemia: a clinical update.
Liang D; Wang Q; Zhang W; Tang H; Song C; Yan Z; Liang Y; Wang H
Mol Cancer; 2024 Jan; 23(1):25. PubMed ID: 38273387
[TBL] [Abstract][Full Text] [Related]
6. The JAK/STAT signaling pathway: from bench to clinic.
Hu X; Li J; Fu M; Zhao X; Wang W
Signal Transduct Target Ther; 2021 Nov; 6(1):402. PubMed ID: 34824210
[TBL] [Abstract][Full Text] [Related]
7. Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
Mughal TI; Girnius S; Rosen ST; Kumar S; Wiestner A; Abdel-Wahab O; Kiladjian JJ; Wilson WH; Van Etten RA
Leuk Lymphoma; 2014 Sep; 55(9):1968-79. PubMed ID: 24206094
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
Quintás-Cardama A; Verstovsek S
Clin Cancer Res; 2013 Apr; 19(8):1933-40. PubMed ID: 23406773
[TBL] [Abstract][Full Text] [Related]
9. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential.
Tzeng HT; Chyuan IT; Lai JH
Biochem Pharmacol; 2021 Nov; 193():114760. PubMed ID: 34492272
[TBL] [Abstract][Full Text] [Related]
10. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer.
Xue C; Yao Q; Gu X; Shi Q; Yuan X; Chu Q; Bao Z; Lu J; Li L
Signal Transduct Target Ther; 2023 May; 8(1):204. PubMed ID: 37208335
[TBL] [Abstract][Full Text] [Related]
11. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional targets of Drosophila JAK/STAT pathway signalling as effectors of haematopoietic tumour formation.
Bina S; Wright VM; Fisher KH; Milo M; Zeidler MP
EMBO Rep; 2010 Mar; 11(3):201-7. PubMed ID: 20168330
[TBL] [Abstract][Full Text] [Related]
13. An immunoevasive strategy through clinically-relevant pan-cancer genomic and transcriptomic alterations of JAK-STAT signaling components.
Chang WH; Lai AG
Mol Med; 2019 Nov; 25(1):46. PubMed ID: 31684858
[TBL] [Abstract][Full Text] [Related]
14. JAK-STAT signaling as an ARDS therapeutic target: Status and future trends.
Zhang Y; Gao Z; Jiang F; Yan H; Yang B; He Q; Luo P; Xu Z; Yang X
Biochem Pharmacol; 2023 Feb; 208():115382. PubMed ID: 36528067
[TBL] [Abstract][Full Text] [Related]
15. The JAK-STAT pathway: a therapeutic target in hematological malignancies.
Ferrajoli A; Faderl S; Ravandi F; Estrov Z
Curr Cancer Drug Targets; 2006 Dec; 6(8):671-9. PubMed ID: 17168672
[TBL] [Abstract][Full Text] [Related]
16. Human diseases caused by impaired signal transducer and activator of transcription and Janus kinase signaling.
Chaimowitz NS; Forbes LR
Curr Opin Pediatr; 2019 Dec; 31(6):843-850. PubMed ID: 31693596
[TBL] [Abstract][Full Text] [Related]
17. Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy.
Bose S; Banerjee S; Mondal A; Chakraborty U; Pumarol J; Croley CR; Bishayee A
Cells; 2020 Jun; 9(6):. PubMed ID: 32545187
[TBL] [Abstract][Full Text] [Related]
18. [Research Advances of JAK/STAT Signaling Pathway in Lung Cancer].
Yang X; Tang Z; Zhang P; Zhang L
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):45-51. PubMed ID: 30674393
[TBL] [Abstract][Full Text] [Related]
19. JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions.
Beckman JD; DaSilva A; Aronovich E; Nguyen A; Nguyen J; Hargis G; Reynolds D; Vercellotti GM; Betts B; Wood DK
J Thromb Haemost; 2023 May; 21(5):1366-1380. PubMed ID: 36738826
[TBL] [Abstract][Full Text] [Related]
20. The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumors.
Zhao R; Hu Z; Zhang X; Huang S; Yu G; Wu Z; Yu W; Lu J; Ruan B
Cell Commun Signal; 2024 Jan; 22(1):68. PubMed ID: 38273295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]